# SAM #36C26127N0055

Award for 54 PLUVICTO Treatments for VA Northern California, with an Option for 36 More

**Buyer:** VA Network Contracting Office 21
**Posted:** October 01, 2026
**Identifier:** 36C26127N0055
**NAICS:** 325412, 424210

The Department of Veterans Affairs awarded a purchase of PLUVICTO for Veterans in Northern California.
- **Government buyer:** Department of Veterans Affairs, VISN 21 and VA Northern California Health Care System; Regional Procurement Office West, Network Contracting Office 21.
- **OEM and vendor:** **Novartis Pharmaceuticals Corporation**, manufacturer and supplier of PLUVICTO.
- **Product:** 54 treatments of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), NDC 69488-0010-61, with an option for 36 additional treatments.
- **Use and treatment requirements:** Targeted radiopharmaceutical therapy for adult Veterans with PSMA-positive metastatic castration-resistant prostate cancer. The treatment course is six cycles per Veteran, administered every six weeks.
- **Notable procurement condition:** The VA describes the requirement as limited-source, citing the mandatory-use NAC pharmaceutical contract and the absence of another NAC distributor for the required product.
- **Award amount:** $3,086,483.40, including an option to increase the quantity.

### Description

<p>Awardee: NOVARTIS PHARMACEUTICALS CORPORATION</p>

<p>Award Amount:&nbsp;$3,086,483.40 (including option to increase quantity)</p>

<p>Period of Performance: 10/01/2026 - 09/30/2027</p>

<p>Limited Source Justification is attached.</p>

[View original listing](https://sam.gov/opp/f6b41ed0cab84404b33f2ddae965dea4/view)